Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (51-60 of 182) with videos related to

Pageof 19
Sort By:
Age and Ageing|November 13, 2010
Human stem cell therapy in ischaemic stroke: a reviewSoma Banerjee, Deborah Williamson, Nagy Habib, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 25, 2018
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trialsRichard S Nicholas, Erika Han, Joel Raffel, et al.
Annals of Clinical and Translational Neurology|July 22, 2024
Investigating cortical hypoxia in multiple sclerosis via time-domain near-infrared spectroscopyThomas Williams, Frédéric Lange, Kenneth J Smith, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 18, 2024
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in EnglandRaffaele Palladino, Jeremy Chataway, Mekha Mathew, et al.
Neurology. Genetics|July 23, 2024
<i>CSF1R</i>-Related Disorder: Prevalence of <i>CSF1R</i> Variants and Their Clinical Significance in the UK PopulationCharles Wade, Kyle Runeckles, Jeremy Chataway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 9, 2023
Assessing heterogeneity of treatment effect in multiple sclerosis trialsMaria Pia Sormani, Jeremy Chataway, David M Kent, et al.
Multiple Sclerosis and Related Disorders|April 12, 2016
Bone health in patients with multiple sclerosis relapsesOlwen Murphy, Michael S Zandi, Nitzan Lindenberg, et al.
Disability and Rehabilitation|September 30, 2016
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionalsEmer O'Loughlin, Susan Hourihan, Jeremy Chataway, et al.
Current Medical Research and Opinion|March 18, 2021
Secondary progressive multiple sclerosis: a systematic review of costs and health state utilitiesJeremy Chataway, Niamh Murphy, Vivek Khurana, et al.
Health and Quality of Life Outcomes|September 28, 2011
A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)Afsane Riazi, Bernadette Porter, Jeremy Chataway, et al.
Pageof 19

Showing results (51-60 of 182) with videos related to

Sort By:
Pageof 19
Age and Ageing|November 13, 2010
Human stem cell therapy in ischaemic stroke: a reviewSoma Banerjee, Deborah Williamson, Nagy Habib, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 25, 2018
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trialsRichard S Nicholas, Erika Han, Joel Raffel, et al.
Annals of Clinical and Translational Neurology|July 22, 2024
Investigating cortical hypoxia in multiple sclerosis via time-domain near-infrared spectroscopyThomas Williams, Frédéric Lange, Kenneth J Smith, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 18, 2024
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in EnglandRaffaele Palladino, Jeremy Chataway, Mekha Mathew, et al.
Neurology. Genetics|July 23, 2024
<i>CSF1R</i>-Related Disorder: Prevalence of <i>CSF1R</i> Variants and Their Clinical Significance in the UK PopulationCharles Wade, Kyle Runeckles, Jeremy Chataway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 9, 2023
Assessing heterogeneity of treatment effect in multiple sclerosis trialsMaria Pia Sormani, Jeremy Chataway, David M Kent, et al.
Multiple Sclerosis and Related Disorders|April 12, 2016
Bone health in patients with multiple sclerosis relapsesOlwen Murphy, Michael S Zandi, Nitzan Lindenberg, et al.
Disability and Rehabilitation|September 30, 2016
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionalsEmer O'Loughlin, Susan Hourihan, Jeremy Chataway, et al.
Current Medical Research and Opinion|March 18, 2021
Secondary progressive multiple sclerosis: a systematic review of costs and health state utilitiesJeremy Chataway, Niamh Murphy, Vivek Khurana, et al.
Health and Quality of Life Outcomes|September 28, 2011
A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)Afsane Riazi, Bernadette Porter, Jeremy Chataway, et al.
Pageof 19